Brown adipose tissue--a new role in humans?
New targets for pharmacological interventions are of great importance to combat the epidemic of obesity. Brown adipose tissue could potentially represent one such target. Unlike white adipose tissue, brown adipose tissue has the ability to dissipate energy by producing heat rather than storing it as triglycerides. In small mammals, the presence of active brown adipose tissue is pivotal for the maintenance of body temperature and possibly to protect against the detrimental effects of surplus energy intake. Animal studies have shown that expansion and/or activation of brown adipose tissue counteracts diet-induced weight gain and related disorders such as type 2 diabetes mellitus. Several independent studies have now confirmed the presence of functional brown adipose tissue in adult humans, for whom this tissue is probably metabolically beneficial given its association with both low BMI and low total adipose tissue content. Over the past few years, knowledge of the transcriptional control and development of brown adipose tissue has increased substantially. Thus, several possible targets that may be useful for the expansion and/or activation of this tissue by pharmacological means have been identified. Whether or not brown adipose tissue will be useful in the battle against obesity remains to be seen. However, this possibility is certainly well worth exploring.
Lidell
Martin E
ME
Department of Medical and Clinical Genetics, Institute of Biomedicine, University of Gothenburg, Box 440, SE-40530 Gothenburg, Sweden.
Enerbäck
Sven
S
D000222:Adaptation, Physiological; D000273:Adipose Tissue / Q000033:anatomy & histology; D002001:Adipose Tissue, Brown / Q000187:drug effects / Q000254:growth & development / Q000502:physiology* / Q000637:transplantation; D000322:Adrenergic Agonists / Q000627:therapeutic use; D058666:Adrenergic beta-2 Receptor Agonists; D000818:Animals; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D022722:Thermogenesis / Q000502:physiology; D045162:Thiazolidinediones / Q000627:therapeutic use; D023822:Tissue Engineering
D000322:Adrenergic Agonists; D058666:Adrenergic beta-2 Receptor Agonists; D045162:Thiazolidinediones
Genes Dev. 2008 May 15;22(10):1269-75
18483216
Trends Pharmacol Sci. 2009 Aug;30(8):387-96
19595466
Cell Metab. 2007 Jul;6(1):38-54
17618855
N Engl J Med. 2009 Apr 9;360(15):1509-17
19357406
Genes Dev. 2007 Jun 15;21(12):1443-55
17575046
Diabetes. 2009 Jul;58(7):1526-31
19401428
J Clin Invest. 1998 Jul 15;102(2):412-20
9664083
Eur J Appl Physiol Occup Physiol. 1981;46(4):339-45
6266825
Nature. 1983 Oct 20-26;305(5936):712-3
6633638
Nat Rev Mol Cell Biol. 2005 Mar;6(3):248-61
15738989
Genes Dev. 2009 Apr 1;23(7):788-97
19339685
J Appl Physiol. 1961 Nov;16:1011-5
13883973
Radiology. 1973 May;107(2):279-81
4695890
Science. 2002 Aug 2;297(5582):843-5
12161655
Endocrinology. 1996 Jan;137(1):21-9
8536614
J Biol Chem. 2003 Aug 8;278(32):29385-8
12788929
FASEB J. 2009 Sep;23(9):3113-20
19417078
Metabolism. 1983 Mar;32(3):257-61
6827996
Am J Physiol. 1960 Mar;198:471-5
13814518
Nature. 1993 Dec 23-30;366(6457):740-2
8264795
Am J Physiol Cell Physiol. 2000 Sep;279(3):C670-81
10942717
Exp Clin Endocrinol Diabetes. 2007 May;115(5):303-7
17516293
Clin Sci (Lond). 1983 Jan;64(1):19-23
6337007
Pharmacol Res. 2006 Jun;53(6):482-91
16644234
Am J Physiol. 1982 Jun;242(6):E353-9
6953766
Cell Metab. 2009 Feb;9(2):203-9
19187776
Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1018-22
17225118
Nature. 1996 Apr 25;380(6576):677
8614460
J Biol Chem. 1985 Dec 25;260(30):16250-4
2999153
Nature. 1979 Sep 6;281(5726):31-5
551265
Nature. 2008 Aug 21;454(7207):1000-4
18719589
J Clin Invest. 2004 Nov;114(9):1281-9
15520860
N Engl J Med. 2007 Jan 18;356(3):213-5
17229948
Cell. 1998 Mar 20;92(6):829-39
9529258
Genes Dev. 2008 May 15;22(10):1397-409
18483224
Physiol Rev. 1969 Apr;49(2):330-425
4888392
Am J Physiol. 1994 Jul;267(1 Pt 2):R115-23
7914069
Physiol Rev. 2004 Jan;84(1):277-359
14715917
Science. 2008 Oct 24;322(5901):583-6
18801968
Nat Rev Endocrinol. 2010 Apr;6(4):195-213
20195269
J Clin Invest. 2000 Jul;106(2):171-6
10903330
Nature. 2009 Aug 27;460(7259):1154-8
19641492
Pharmacol Res. 2009 Apr;59(4):221-34
19429463
J Clin Endocrinol Metab. 1998 Jul;83(7):2441-4
9661625
Cell. 2007 Oct 19;131(2):242-56
17956727
J Nucl Med. 2003 Aug;44(8):1267-70
12902417
Diabetes. 2009 Nov;58(11):2583-7
19696186
Nature. 1998 Oct 22;395(6704):763-70
9796811
Nature. 2000 Apr 6;404(6778):652-60
10766252
Nat Genet. 2003 Sep;35(1):49-56
12910269
Can J Physiol Pharmacol. 1986 May;64(5):609-14
3730946
N Engl J Med. 2009 Apr 9;360(15):1500-8
19357405
FASEB J. 2001 Sep;15(11):2048-50
11511509
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4401-6
17360536
Nature. 1984 May 10-16;309(5964):163-5
6325935
Dev Biol. 2006 Aug 1;296(1):164-76
16730693
J Lipid Res. 2007 Jan;48(1):41-51
17041251
Am J Physiol. 1982 Apr;242(4):E253-61
6278959
Trends Pharmacol Sci. 1996 Oct;17(10):373-81
8979772
Hum Pathol. 1983 Dec;14(12):1044-52
6642494
Endocr Rev. 2003 Feb;24(1):78-90
12588810
Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E444-52
17473055
Diabetes. 2005 Jun;54(6):1657-63
15919786
Diabetes. 1998 Apr;47(4):507-14
9568680
Clin Nucl Med. 2006 Apr;31(4):193-6
16550009
Cell. 2001 Sep 7;106(5):563-73
11551504
J Clin Invest. 1997 Jul 15;100(2):270-8
9218503
Nature. 1997 May 1;387(6628):94-7
9139828
Nature. 1997 May 1;387(6628):90-4
9139827
FEBS J. 2009 Oct;276(20):5729-37
19754874
J Anat. 1972 May;112(Pt 1):35-9
5086212
Int J Obes (Lond). 2008 Aug;32(8):1240-9
18574485
Nature. 2008 Aug 21;454(7207):961-7
18719582
Cancer. 1952 Mar;5(2):364-8
14905423
J Cell Sci. 1992 Dec;103 ( Pt 4):931-42
1362571
J Nutr. 1982 Sep;112(9):1663-72
7108638
N Engl J Med. 2009 Apr 9;360(15):1518-25
19357407